

# Stergios A. Polyzos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2027554/publications.pdf>

Version: 2024-02-01

422  
papers

13,036  
citations

26630

56  
h-index

38395

95  
g-index

427  
all docs

427  
docs citations

427  
times ranked

13933  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease. <i>Minerva Endocrinology</i> , 2023, 48, .	1.1	2
2	Nonalcoholic fatty liver disease: lifestyle and quality of life. <i>Hormones</i> , 2022, 21, 41-49.	1.9	23
3	Correspondence on 'Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis' by Rizos <i>et al</i>. <i>Heart</i> , 2022, 108, 657.1-657.	2.9	3
4	The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis. <i>Bone</i> , 2022, 158, 116354.	2.9	2
5	Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need. <i>Current Medical Research and Opinion</i> , 2022, 38, 885-888.	1.9	5
6	Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study. <i>Clinical Nutrition</i> , 2022, 41, 1281-1289.	5.0	18
7	GMâ€CSF as a potential candidate of a vaccineâ€induced reduction of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2022, 27, e12884.	3.5	0
8	Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 852-862.	1.3	7
9	Impact of <sc><i>Helicobacter pylori</i></sc>â€related metabolic syndrome with hyperhomocysteinemia on extragastric pathologies. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 407-408.	2.8	2
10	Cilofexor for the Treatment of Nonalcoholic Steatohepatitis. <i>Current Vascular Pharmacology</i> , 2022, 20, 111-113.	1.7	3
11	Letter to the Editor Regarding â€The Association of <i>Helicobacter pylori</i> , Eradication, and Early Complications of Laparoscopic Sleeve Gastrectomyâ€by Abeid et al.. <i>Obesity Surgery</i> , 2022, 32, 2079.	2.1	2
12	<i>Helicobacter pylori</i>, gastric microbiota and gastric cancer relationship: Unrolling the tangle. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 959-972.	2.0	17
13	Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease. <i>Hormones</i> , 2022, 21, 375-381.	1.9	12
14	Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. <i>Current Obesity Reports</i> , 2022, 11, 166-179.	8.4	18
15	Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1702-1720.	4.4	13
16	Circulating adiponectin in patients with nonalcoholic fatty liver diseaseâ€related liver fibrosis: A systematic review and a metaâ€analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1853-1864.	2.8	5
17	Comments on â€dose-related meta-analysis for omega-3 fatty acids supplementation on major adverse cardiovascular eventsâ€: <i>Clinical Nutrition</i> , 2022, , .	5.0	1
18	Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer. <i>Hormones</i> , 2022, 21, 513-514.	1.9	3

#	ARTICLE	IF	CITATIONS
19	Combination Therapies for Nonalcoholic Fatty Liver Disease. <i>Journal of Personalized Medicine</i> , 2022, 12, 1166.	2.5	18
20	Alzheimer's disease and gastrointestinal microbiota; impact of <i>Helicobacter pylori</i> infection involvement. <i>International Journal of Neuroscience</i> , 2021, 131, 289-301.	1.6	38
21	Similar late effects of a 7-week orthodox religious fasting and a time restricted eating pattern on anthropometric and metabolic profiles of overweight adults. <i>International Journal of Food Sciences and Nutrition</i> , 2021, 72, 248-258.	2.8	22
22	A mutation in NOTCH2 gene first associated with Hajdu-Cheney syndrome in a Greek family: diversity in phenotype and response to treatment. <i>Endocrine</i> , 2021, 71, 208-215.	2.3	3
23	Update on the association between non-alcoholic fatty liver disease and <i>Helicobacter pylori</i> infection. <i>International Journal of Clinical Practice</i> , 2021, 75, e13737.	1.7	6
24	Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough. <i>Journal of Clinical Densitometry</i> , 2021, 24, 338-340.	1.2	9
25	Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing. <i>Medical Hypotheses</i> , 2021, 146, 110379.	1.5	8
26	Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease. <i>Archives of Medical Research</i> , 2021, 52, 25-37.	3.3	112
27	<i>Helicobacter pylori</i> , Sleeve Gastrectomy, and Gastroesophageal Reflux Disease: Is There a Relation?. <i>Obesity Surgery</i> , 2021, 31, 1839-1840.	2.1	3
28	Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation. <i>Calcified Tissue International</i> , 2021, 108, 587-594.	3.1	8
29	Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation. <i>Journal of Clinical Densitometry</i> , 2021, 24, 591-596.	1.2	7
30	A potential impact of <i>Helicobacter pylori</i> -related sarcopenia on severity of portal hypertension. <i>Liver International</i> , 2021, 41, 1168-1169.	3.9	2
31	Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion. <i>Endocrine</i> , 2021, 73, 223-225.	2.3	0
32	The trimebutine effect on <i>Helicobacter pylori</i> -related gastrointestinal tract and brain disorders: A hypothesis. <i>Neurochemistry International</i> , 2021, 144, 104938.	3.8	9
33	Diabetes mellitus: 100 years since the discovery of insulin. <i>Metabolism: Clinical and Experimental</i> , 2021, 118, 154737.	3.4	9
34	Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations. <i>Maturitas</i> , 2021, 147, 19-25.	2.4	19
35	Denosumab for the treatment of primary pediatric osteoporosis. <i>Osteoporosis International</i> , 2021, 32, 2377-2381.	3.1	6
36	<i>Helicobacter pylori</i> infection and diabetes mellitus. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 845-846.	3.6	4

#	ARTICLE	IF	CITATIONS
37	Micro-Ultrasoundâ€“Guided vs Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2021, 205, 1254-1262.	0.4	52
38	Potential impact of <i>Helicobacter pylori</i> -related metabolic syndrome and Galectin-3 on liver, chronic kidney and brain disorders. <i>Metabolism: Clinical and Experimental</i> , 2021, 118, 154736.	3.4	6
39	Î™risin levels in postmenopausal women with an incident hip fracture. <i>Endocrine</i> , 2021, 73, 719-722.	2.3	2
40	The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4155-e4162.	3.6	31
41	Irisin in nonalcoholic fatty liver disease: need for an updated meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2021, 121, 154818.	3.4	2
42	<i>Helicobacter pylori</i> -Related Metabolic Parameters and Premalignant Gastric Mucosa Histological Lesions in Swiss Bariatric Patients. <i>Microorganisms</i> , 2021, 9, 1361.	3.6	11
43	Circulating tumor necrosis factorâ€“Î± levels in nonâ€“alcoholic fatty liver disease: A systematic review and a metaâ€“analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3002-3014.	2.8	30
44	Review article: nonâ€“alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1013-1025.	3.7	47
45	Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?. <i>Metabolism: Clinical and Experimental</i> , 2021, 121, 154796.	3.4	3
46	Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. <i>European Journal of Pharmacology</i> , 2021, 907, 174272.	3.5	14
47	Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154781.	3.4	10
48	Impact of <i>Helicobacter pylori</i> -related Metabolic Syndrome and Gastroesophageal Reflux Disease on the Risk of Acute Myocardial Infarction. <i>Journal of Neurogastroenterology and Motility</i> , 2021, 27, 147-148.	2.4	3
49	Impact of <i>Helicobacter pylori</i> -related Microbial Dysbiosis in the Pathogenesis of Metabolic Syndrome and Gastrointestinal Dysmotility Disorders. <i>Journal of Neurogastroenterology and Motility</i> , 2021, 27, 653-654.	2.4	0
50	Impact of Body Mass Index on the Age of Relapsing-Remitting Multiple Sclerosis Onset: A Retrospective Study. <i>Neurology International</i> , 2021, 13, 517-526.	2.8	3
51	Role of autophagy in gastric carcinogenesis. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1244-1262.	2.0	5
52	Impact of <i>Helicobacter pylori</i> -Related Metabolic Syndrome Parameters on Arterial Hypertension. <i>Microorganisms</i> , 2021, 9, 2351.	3.6	21
53	Hypophosphatasia. <i>Journal of Clinical Medicine</i> , 2021, 10, 5676.	2.4	16
54	Adult hypophosphatasia treated with reduced frequency of teriparatide dosing. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2021, 21, 584-589.	0.1	1

#	ARTICLE	IF	CITATIONS
55	Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. <i>Endocrine</i> , 2020, 67, 1-8.	2.3	150
56	Selenium and selenoprotein P in nonalcoholic fatty liver disease. <i>Hormones</i> , 2020, 19, 61-72.	1.9	30
57	<i>Helicobacter pylori</i> eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis. <i>Helicobacter</i> , 2020, 25, e12666.	3.5	12
58	Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e390-e400.	3.6	29
59	Impact of nitric oxide's bidirectional role on glaucoma: focus on <i>Helicobacter pylori</i> -related nitrosative stress. <i>Annals of the New York Academy of Sciences</i> , 2020, 1465, 10-28.	3.8	8
60	Influence of <i>Helicobacter pylori</i> -connected metabolic syndrome on non-alcoholic fatty liver disease and its related colorectal neoplasm high risk. <i>Liver International</i> , 2020, 40, 475-476.	3.9	11
61	Potential impact of <i>Helicobacter pylori</i> -related Galectin-3 on chronic kidney, cardiovascular and brain disorders in decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2020, 52, 121-123.	0.9	12
62	Potential Impact of <i>Helicobacter pylori</i> Infection on Reflux Disease Sequence. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 200-201.	2.2	1
63	Letter: <i>Helicobacter pylori</i> in proton pump inhibitor-associated biliary disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 313-314.	3.7	0
64	Treatment of nonalcoholic fatty liver disease: from adult trials to perspectives in the management of children and adolescents. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 247-251.	1.8	7
65	Nonalcoholic fatty liver disease in males with low testosterone concentrations. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1571-1577.	3.6	16
66	Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial. <i>Medicina (Lithuania)</i> , 2020, 56, 339.	2.0	9
67	Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis. <i>Annals of Hepatology</i> , 2020, 19, 579-580.	1.5	0
68	Reconsidering the "protective" hypothesis of <i>Helicobacter pylori</i> infection in eosinophilic esophagitis. <i>Annals of the New York Academy of Sciences</i> , 2020, 1481, 59-71.	3.8	12
69	Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154318.	3.4	28
70	<i>Helicobacter pylori</i> infection as a potential risk factor for multiple sclerosis. <i>Medical Hypotheses</i> , 2020, 143, 110135.	1.5	11
71	Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1913-1919.	3.6	9
72	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. <i>Metabolism: Clinical and Experimental</i> , 2020, 113, 154413.	3.4	45

#	ARTICLE	IF	CITATIONS
73	Letter to the editor re: Li et al. (2020), "The potential role of bacteria in pancreatic cancer: A systematic review". <i>Carcinogenesis</i> , 2020, 41, 539-540.	2.8	0
74	The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. <i>Bone</i> , 2020, 138, 115478.	2.9	26
75	Association between Active <i>Helicobacter pylori</i> Infection and Glaucoma: A Systematic Review and Meta-Analysis. <i>Microorganisms</i> , 2020, 8, 894.	3.6	21
76	Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 73-76.	1.5	2
77	Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154203.	3.4	88
78	Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against <i>Helicobacter pylori</i> Infection in Greece: Do National Health Policy-Makers Need to Care?. <i>Medicina (Lithuania)</i> , 2020, 56, 133.	2.0	3
79	Association between <i>Helicobacter pylori</i> infection and Guillain-Barré Syndrome: A meta-analysis. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13218.	3.4	21
80	Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. <i>Metabolism: Clinical and Experimental</i> , 2020, 104, 154144.	3.4	30
81	Combination and sequential treatment in women with postmenopausal osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 477-490.	1.8	33
82	Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. <i>Current Vascular Pharmacology</i> , 2020, 18, 172-181.	1.7	54
83	Impact of <i>Helicobacter pylori</i> -linked metabolic syndrome on nonalcoholic fatty liver disease and its connected atrial fibrillation risk. <i>Liver International</i> , 2020, 40, 2036-2037.	3.9	8
84	Active <i>Helicobacter pylori</i> Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 933.	2.4	48
85	A potential impact of <i>Helicobacter pylori</i> infection on minimal hepatic encephalopathy pathobiology. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 405-412.	0.9	3
86	Rodent models of obesity. <i>Minerva Endocrinologica</i> , 2020, 45, 243-263.	1.8	20
87	National consensus on <i>Helicobacter pylori</i> infection: the next-day challenge. <i>Annals of Gastroenterology</i> , 2020, 33, 324-325.	0.6	0
88	Letter: <i>Helicobacter pylori</i> infection and its role in oesophageal adenocarcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1215-1216.	3.7	0
89	Homocysteine in nonalcoholic steatohepatitis: seemingly a paradox revisited. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 270-271.	0.9	4
90	The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. <i>Exploration of Medicine</i> , 2020, 1, 170-183.	1.5	4

#	ARTICLE	IF	CITATIONS
91	Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2220-2228.	2.8	103
92	A perspective on risk factors for esophageal adenocarcinoma: emphasis on <i>Helicobacter pylori</i> infection. <i>Annals of the New York Academy of Sciences</i> , 2019, 1452, 12-17.	3.8	26
93	Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society. <i>Bone</i> , 2019, 127, 401-418.	2.9	33
94	Asporin levels are low in patients with nonalcoholic fatty liver disease and increase after vitamin E treatment. <i>Hormones</i> , 2019, 18, 519-521.	1.9	8
95	Off-label uses of denosumab in metabolic bone diseases. <i>Bone</i> , 2019, 129, 115048.	2.9	37
96	Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. <i>European Journal of Pharmacology</i> , 2019, 863, 172661.	3.5	38
97	Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?. <i>Metabolism: Clinical and Experimental</i> , 2019, 93, 100-102.	3.4	11
98	Comments to the Editor concerning the paper entitled "The microbiome and ophthalmic disease" by Baim et al.. <i>Experimental Biology and Medicine</i> , 2019, 244, 430-432.	2.4	5
99	The Effect of Trimebutine and/or <i>Helicobacter pylori</i> Eradication on the Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, and Functional Dyspepsia Overlapping Disorders. <i>Journal of Neurogastroenterology and Motility</i> , 2019, 25, 473-474.	2.4	4
100	The relationship between <i>Helicobacter pylori</i> -related microbiota dysbiosis and gastrointestinal tract pathologies. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 806-807.	1.5	0
101	Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 66-82.	3.4	72
102	<i>Helicobacter pylori</i> infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, iii-v.	3.4	16
103	<i>Helicobacter pylori</i> infection and gastrointestinal tract cancer biology: considering a double-edged sword reflection. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 2487-2488.	5.4	3
104	CHAI and MACK as noninvasive indices for nonalcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 1587-1587.	3.9	2
105	Metabolic syndrome components including high abdominal obesity and sarcopenia in patients with inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2019, 32, 214.	0.6	2
106	Impact of <i>Helicobacter pylori</i> and/or <i>Helicobacter pylori</i> -related metabolic syndrome on incidence of all-cause and Alzheimer's dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 723-725.	0.8	16
107	Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, vi-xi.	3.4	6
108	<i>Helicobacter pylori</i> infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy. <i>Helicobacter</i> , 2019, 24, e12588.	3.5	16

#	ARTICLE	IF	CITATIONS
109	Acute Liver Failure. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 89-101.	2.2	9
110	Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. <i>Metabolism: Clinical and Experimental</i> , 2019, 101, 154005.	3.4	83
111	Vitamin D Deficiency and Unclear Abdominal Pain in Patients from Low- and Middle-Income Countries. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4607.	2.6	2
112	Impact of occupational stress on irritable bowel syndrome pathophysiology and potential management in active duty noncombat Greek military personnel: a multicenter prospective survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 954-963.	1.6	2
113	<i>Helicobacter pylori</i> Infection: One More Contributor to Nonalcoholic Fatty Liver Disease Pathophysiology. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 624-626.	2.2	3
114	Serum Levels of Activins, Follistatins, and Growth Factors in Neoplasms of the Breast: A Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 349-358.	3.6	15
115	Adiponectin and vitamin D-binding protein concentrations are independently associated in apparently healthy women but not men: a validation cohort. <i>Hormones</i> , 2019, 18, 99-102.	1.9	1
116	Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 598-602.	1.2	18
117	Obesity: seize the day, fight the fat. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 1-5.	3.4	24
118	Pharmacotherapy of obesity: Available medications and drugs under investigation. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 170-192.	3.4	184
119	Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls. <i>Hormone and Metabolic Research</i> , 2019, 51, 112-119.	1.5	7
120	Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 82-97.	3.4	679
121	Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort. <i>Hormone and Metabolic Research</i> , 2019, 51, 134-140.	1.5	32
122	Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview. <i>Hormones</i> , 2019, 18, 65-70.	1.9	12
123	Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. <i>Bone</i> , 2019, 120, 44-49.	2.9	19
124	Gastroesophageal reflux disease, irritable bowel syndrome and functional dyspepsia as overlapping conditions: focus on effect of trimebutine. <i>Annals of Gastroenterology</i> , 2019, 32, 318.	0.6	4
125	Molecular Links Between Alzheimer's Disease and Gastrointestinal Microbiota: Emphasis on <i>Helicobacter pylori</i> Infection Involvement. <i>Current Molecular Medicine</i> , 2019, 20, 3-12.	1.3	10
126	Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives. <i>Current Vascular Pharmacology</i> , 2019, 17, 546-555.	1.7	51

#	ARTICLE	IF	CITATIONS
127	Microbes and Alzheimer' disease: lessons from H. pylori and GUT microbiota. European Review for Medical and Pharmacological Sciences, 2019, 23, 1845-1846.	0.7	9
128	Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass. Journal of Musculoskeletal Neuronal Interactions, 2019, 19, 253-257.	0.1	0
129	Potential Impact of Helicobacter Pylori on Hepatic Encephalopathy Pathophysiology. Digestive Diseases and Sciences, 2018, 63, 1087-1088.	2.3	3
130	Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?. Calcified Tissue International, 2018, 103, 107-108.	3.1	7
131	Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?. Hepatology, 2018, 68, 389-389.	7.3	26
132	Juvenile Paget disease. Metabolism: Clinical and Experimental, 2018, 80, 15-26.	3.4	32
133	Sixty-six years of Metabolism, Clinical and Experimental: The journey of a journal and opportunities and challenges looking ahead. Metabolism: Clinical and Experimental, 2018, 78, A4-A9.	3.4	2
134	A potential impact of Helicobacter pylori -related galectin-3 in neurodegeneration. Neurochemistry International, 2018, 113, 137-151.	3.8	21
135	Comment on "Therapeutic Application of an Extract of Helicobacter pylori Ameliorates the Development of Allergic Airway Disease". Journal of Immunology, 2018, 200, 3027.1-3027.	0.8	0
136	THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. European Journal of Endocrinology, 2018, 179, R31-R45.	3.7	94
137	Outliers of bone metabolic diseases. Metabolism: Clinical and Experimental, 2018, 80, 1-4.	3.4	4
138	Pharmacotherapy of type 2 diabetes: An update. Metabolism: Clinical and Experimental, 2018, 78, 13-42.	3.4	144
139	Irisin in metabolic diseases. Endocrine, 2018, 59, 260-274.	2.3	178
140	Review: Impact of <i>Helicobacter pylori</i> on Alzheimer's disease: What do we know so far?. Helicobacter, 2018, 23, e12454.	3.5	88
141	Adiponectin and vitamin D-binding protein are independently associated at birth in both mothers and neonates. Endocrine, 2018, 59, 164-174.	2.3	10
142	Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. Hormones, 2018, 17, 573-579.	1.9	6
143	H. pylori and Parkinson's disease: Meta-analyses including clinical severity. Clinical Neurology and Neurosurgery, 2018, 175, 16-24.	1.4	78
144	Impact of <i>Helicobacter pylori</i> and/or <i>Helicobacter pylori</i> -related metabolic syndrome on gastroesophageal reflux disease-Barrett's esophagus-esophageal adenocarcinoma sequence. Helicobacter, 2018, 23, e12534.	3.5	10

#	ARTICLE	IF	CITATIONS
145	Helicobacter pylori Infection and Gastroesophageal Reflux Disease-Barrett's Esophagus-Esophageal Adenocarcinoma Sequence. American Journal of Gastroenterology, 2018, 113, 1723-1724.	0.4	6
146	Potential impact of Helicobacter pylori-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis. Metabolism: Clinical and Experimental, 2018, 87, 18-24.	3.4	53
147	Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis. Endocrine, 2018, 62, 487-489.	2.3	1
148	Sarcopenic obesity. Hormones, 2018, 17, 321-331.	1.9	129
149	Multiple Bidirectionality Brain-Gut Interactions in Patients With Inflammatory Bowel Disease. Gastroenterology, 2018, 155, 1651-1652.	1.3	6
150	The Emerging Role of Helicobacter Pylori-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration. Current Molecular Medicine, 2018, 17, 389-404.	1.3	23
151	Thyroid dysfunction and non-alcoholic fatty liver disease. Minerva Endocrinology, 2018, 43, 367-376.	1.1	12
152	Potential Impact of Active Helicobacter pylori Infection with or without Concomitant Metabolic Syndrome on Colorectal Cancer Invasion and Mortality. Israel Medical Association Journal, 2018, 20, 725-726.	0.1	0
153	Helicobacter pylori-related chronic hepatitis C infection and the risk for cardiovascular disease. Liver International, 2017, 37, 1082-1082.	3.9	2
154	Impact of reactive oxygen species generation on Helicobacter pylori-related extragastric diseases: a hypothesis. Free Radical Research, 2017, 51, 73-79.	3.3	26
155	Helicobacter pylori eradication to prevent cardio-cerebrovascular disease: Are current data useful for clinical practice?. International Journal of Cardiology, 2017, 233, 92.	1.7	4
156	Helicobacter pylori-related metabolic syndrome as predictor of progression to esophageal carcinoma in a subpopulation-based Barrett's esophagus cohort. Gastrointestinal Endoscopy, 2017, 85, 462-463.	1.0	7
157	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism: Clinical and Experimental, 2017, 71, 17-32.	3.4	208
158	Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. Journal of Bone and Mineral Research, 2017, 32, 1291-1296.	2.8	270
159	Helicobacter pylori on portal hypertension-related hepatic encephalopathy. Immunopharmacology and Immunotoxicology, 2017, 39, 105-106.	2.4	1
160	Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. Metabolism: Clinical and Experimental, 2017, 73, 1-8.	3.4	53
161	Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity. Metabolism: Clinical and Experimental, 2017, 71, 198-201.	3.4	2
162	Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 1805-1809.	4.4	41

#	ARTICLE	IF	CITATIONS
163	Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. <i>Metabolism: Clinical and Experimental</i> , 2017, 71, 182-197.	3.4	96
164	Novel aspects of defensins <sup>™</sup> involvement in virus-induced autoimmunity in the central nervous system. <i>Medical Hypotheses</i> , 2017, 102, 33-36.	1.5	18
165	A potential impact of <i>Helicobacter pylori</i> infection on both obstructive sleep apnea and atrial fibrillation-related stroke. <i>Sleep Medicine</i> , 2017, 34, 256.	1.6	6
166	Letter: <i>Helicobacter pylori</i> -related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 576-577.	3.7	3
167	Obesity and the nervous system: more questions. <i>Lancet Neurology</i> , The, 2017, 16, 772-773.	10.2	1
168	The intriguing connections of leptin to hyperparathyroidism. <i>Endocrine</i> , 2017, 57, 376-387.	2.3	9
169	Letter: <i>Helicobacter pylori</i> in lean and obese patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 637-638.	3.7	3
170	Lipodystrophy: Time for a global registry and randomized clinical trials to assess efficacy, safety and cost-effectiveness of established and novel medications. <i>Metabolism: Clinical and Experimental</i> , 2017, 72, A4-A10.	3.4	14
171	Circulating periostin in patients with nonalcoholic fatty liver disease. <i>Endocrine</i> , 2017, 56, 438-441.	2.3	6
172	Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR- $\beta$ agonists. <i>Metabolism: Clinical and Experimental</i> , 2017, 66, 64-68.	3.4	17
173	Cardio-cerebrovascular disease and <i>Helicobacter pylori</i> -related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. <i>International Journal of Cardiology</i> , 2017, 229, 17-18.	1.7	36
174	<i>Helicobacter pylori</i> infection and esophageal adenocarcinoma: a review and a personal view. <i>Annals of Gastroenterology</i> , 2017, 31, 8-13.	0.6	33
175	Adipose tissue, obesity and non-alcoholic fatty liver disease. <i>Minerva Endocrinology</i> , 2017, 42, 92-108.	1.1	135
176	Endocrine and metabolic disorders interplaying with non-alcoholic fatty liver disease. <i>Minerva Endocrinology</i> , 2017, 42, 89-91.	1.1	6
177	Active <i>Helicobacter pylori</i> Infection Is a Risk Factor for Colorectal Mucosa: Early and Advanced Colonic Neoplasm Sequence. <i>Gut and Liver</i> , 2017, 11, 733-734.	2.9	11
178	Periostin and sclerostin levels in juvenile Paget's disease. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2017, 14, 269.	1.0	2
179	Comment on "Effect of biofilm formation by clinical isolates of <i>Helicobacter pylori</i> on the efflux-mediated resistance to commonly used antibiotics": <i>World Journal of Gastroenterology</i> , 2017, 23, 6194-6196.	3.3	16
180	Prevalence and determinants of type 2 diabetes mellitus in a Greek adult population. <i>Hormones</i> , 2016, 15, 88-98.	1.9	10

#	ARTICLE	IF	CITATIONS
181	Serum Adiponectin And Insulin-Like Growth Factor 1 In Predominantly Female Patients With Thyroid Cancer: Association With The Histologic Characteristics Of The Tumor. <i>Endocrine Practice</i> , 2016, 22, 68-75.	2.1	16
182	Clinical vertebral fractures following denosumab discontinuation. <i>Endocrine</i> , 2016, 54, 271-272.	2.3	35
183	<i>Helicobacter pylori</i> infection and oesophageal adenocarcinoma. <i>Cancer Epidemiology</i> , 2016, 42, 206-207.	1.9	1
184	Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1459-1465.	3.4	19
185	Colchicine to decrease inflammation and fibrosis in patients with metabolic dysregulation. <i>Medical Hypotheses</i> , 2016, 95, 34.	1.5	3
186	Activin A and follistatin in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1550-1558.	3.4	27
187	Emerging and future therapies for nonalcoholic steatohepatitis in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1937-1946.	1.8	42
188	Homocysteine in nonalcoholic steatohepatitis: A reply. <i>European Journal of Internal Medicine</i> , 2016, 35, e40-e41.	2.2	0
189	Potential molecular aspects of <i>Helicobacter pylori</i> -related hyperplastic polyp development and progression. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 851-852.	1.6	0
190	Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1297-1306.	3.4	92
191	Impact of <i>Helicobacter pylori</i> on multiple sclerosis-related clinically isolated syndrome. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 268-275.	2.1	21
192	Periostin on the road to nonalcoholic fatty liver disease. <i>Endocrine</i> , 2016, 51, 4-6.	2.3	4
193	Adipokines in nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1062-1079.	3.4	250
194	Nonalcoholic fatty future disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1007-1016.	3.4	62
195	Fetuin-A levels and free leptin index are reduced in patients with chronic lymphocytic leukemia: a hospital-based case-control study. <i>Leukemia and Lymphoma</i> , 2016, 57, 577-584.	1.3	7
196	Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. <i>Journal of Bone and Mineral Metabolism</i> , 2016, 34, 447-456.	2.7	24
197	Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. <i>Diabetologia</i> , 2016, 59, 30-43.	6.3	186
198	<i>Helicobacter pylori</i> -related ApoE 4 polymorphism may be associated with dysphagic symptoms in older adults. <i>Ecological Management and Restoration</i> , 2016, 29, 842-842.	0.4	11

#	ARTICLE	IF	CITATIONS
199	Prevalence and determinants of type 2 diabetes mellitus in a Greek adult population. <i>Hormones</i> , 2016, , .	1.9	6
200	ÅVaspin, resistin, retinol-binding protein-4, interleukin-1Î± and interleukin-6 in patients with nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2016, 15, 705-14.	1.5	24
201	Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, L89-L90.	3.6	0
202	Novel Advances in the Association Between <i>Helicobacter pylori</i> Infection, Metabolic Syndrome, and Related Morbidity. <i>Helicobacter</i> , 2015, 20, 405-409.	3.5	22
203	Bone Marrow-Derived Stem Cells in Pathogenesis of <i>Helicobacter pylori</i> -Associated Gastrointestinal Cancer. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e129.	2.5	2
204	Polyautoimmunity in a Greek cohort of multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 225-230.	2.1	12
205	CD44 and <i>Helicobacter pylori</i>-related colon oncogenesis. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2015, 36, 1249-1249.	1.1	2
206	<i>Helicobacter pylori</i> â€™Related Impact on Glaucoma Pathophysiology. , 2015, 56, 8029.		8
207	Nonalcoholic fatty liver disease and polycystic ovary syndrome. <i>Annals of Hepatology</i> , 2015, 14, 941-943.	1.5	3
208	Extragastric Diseases and <i>Helicobacter pylori</i>. <i>Helicobacter</i> , 2015, 20, 40-46.	3.5	150
209	Prediction of atheromatic plaque evolution in carotids using features extracted from the arterial geometry. , 2015, 2015, 6556-9.		1
210	<i>Helicobacter pylori</i> Associated With Obstructive Sleep Apnea Might Contribute to Sleep, Cognition, and Driving Performance Disturbances in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1547.	4.4	6
211	Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease. <i>Endocrine</i> , 2015, 49, 560-562.	2.3	16
212	Associations of Estrogen Receptor Alpha and Beta Gene Polymorphisms with Lipid Levels and Insulin Resistance in Men. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 611-617.	3.4	17
213	<i>Helicobacter pylori</i> might contribute to cancer and/or bone marrow-derived stem cell-related gastrointestinal oncogenesis. <i>Oncogene</i> , 2015, 34, 670-670.	5.9	4
214	P1017 : Circulating sclerostin and DICKKOPF-1 in patients with Nonalcoholic Fatty Liver Disease. <i>Journal of Hepatology</i> , 2015, 62, S729.	3.7	0
215	Denosumab in treatment-naÃ¼ve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1291-1297.	3.4	24
216	An update on the validity of irisin assays and the link between irisin and hepatic metabolism. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 937-942.	3.4	50

#	ARTICLE	IF	CITATIONS
217	Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 145-157.	4.1	17
218	Intracellular leptin signaling following effective weight loss. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 888-895.	3.4	8
219	Circulating homocysteine in nonalcoholic fatty liver disease. <i>European Journal of Internal Medicine</i> , 2015, 26, 152-153.	2.2	5
220	<i>Helicobacter pylori</i> infection, dementia and primary open-angle glaucoma: are they connected?. <i>BMC Ophthalmology</i> , 2015, 15, 24.	1.4	29
221	Association between cirrhosis and <i>Helicobacter pylori</i> -related brain pathologies. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 183.	1.6	4
222	Irisin: A true, circulating hormone. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1611-1618.	3.4	48
223	Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. <i>Osteoporosis International</i> , 2015, 26, 2521-2527.	3.1	49
224	Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 299-306.	3.4	16
225	Leptin in Health and Disease: Facts and Expectations at its Twentieth Anniversary. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 5-12.	3.4	49
226	Leptin in nonalcoholic fatty liver disease: A narrative review. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 60-78.	3.4	170
227	Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation. <i>Rheumatology</i> , 2015, 54, 908-914.	1.9	30
228	Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events. <i>International Journal of Obesity</i> , 2015, 39, 156-161.	3.4	95
229	<i>Helicobacter Pylori</i> -Related Vitamin B12 Deficiency: A Potential Contributor in Neuropsychiatric Disorders. <i>Indian Journal of Psychological Medicine</i> , 2015, 37, 475-476.	1.5	3
230	EFFECT OF HELICOBACTER PYLORI ERADICATION ON HEPATIC STEATOSIS, NAFLD FIBROSIS SCORE AND HSENSI IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: a MR imaging-based pilot open-label study. <i>Arquivos De Gastroenterologia</i> , 2014, 51, 261-268.	0.8	30
231	Serum visfatin in nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2014, 13, 150-151.	1.5	3
232	Circulating fetuin-A in patients with pancreatic cancer: a hospital-based case-control study. <i>Biomarkers</i> , 2014, 19, 660-666.	1.9	10
233	<i>Helicobacter pylori</i> might contribute to nonalcoholic fatty liver disease-related cardiovascular events by releasing prothrombotic and proinflammatory factors. <i>Hepatology</i> , 2014, 60, 1450-1451.	7.3	15
234	The Effect of Leptin Replacement on Parathyroid Hormone, RANKL-Osteoprotegerin Axis, and Wnt Inhibitors in Young Women With Hypothalamic Amenorrhea. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2252-E2258.	3.6	25

#	ARTICLE	IF	CITATIONS
235	Letter: low risk of colorectal cancer in a Greek cohort of inflammatory bowel disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1001-1002.	3.7	0
236	A possible impact of common worldwide environmental agents on the prognosis of critically ill cirrhotic patients. <i>Liver International</i> , 2014, 34, 1127-1128.	3.9	1
237	Body mass index and socioeconomic status measured in adolescence, country of origin, and the incidence of gastroesophageal adenocarcinoma in a cohort of 1 million men. <i>Cancer</i> , 2014, 120, 768-768.	4.1	2
238	Letter: apoptosis and hepatic fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 996-996.	3.7	1
239	Association between <i>Helicobacter pylori</i> burden and Alzheimer's disease. <i>European Journal of Neurology</i> , 2014, 21, e100-e100.	3.3	9
240	Eradication of <i>Helicobacter pylori</i> infection might have a positive impact on subpopulations with endoscopic gastro-oesophageal reflux disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 123.	1.6	1
241	Active <i>Helicobacter pylori</i> infection on colorectal mucosa " adenomatous polyp " adenocarcinoma sequence. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 243-244.	1.6	5
242	<i>Helicobacter pylori</i> and Colorectal Cancer Risk"Letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 365-365.	2.5	4
243	Active <i>Helicobacter pylori</i> infection is associated with colorectal mucosa " adenomatous polyp " early and advanced adenocarcinoma sequence. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 381-382.	1.5	2
244	Irisin in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 207-217.	3.4	179
245	Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 161-167.	3.4	69
246	Denosumab Treatment for Juvenile Paget's Disease: Results From Two Adult Patients With Osteoprotegerin Deficiency ("Balkan" Mutation in the <i>TNFRSF11B</i> Gene). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 703-707.	3.6	38
247	<i>Helicobacter pylori</i> -related metabolic syndrome might justify earlier colorectal cancer screening. <i>Gastrointestinal Endoscopy</i> , 2014, 80, 188-189.	1.0	6
248	Circulating Irisin in Healthy, Young Individuals: Day-Night Rhythm, Effects of Food Intake and Exercise, and Associations With Gender, Physical Activity, Diet, and Body Composition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3247-3255.	3.6	133
249	Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months. <i>Osteoporosis International</i> , 2014, 25, 1633-1642.	3.1	111
250	<i>Helicobacter pylori</i> infection, insulin resistance and nonalcoholic fatty liver disease. <i>Medical Hypotheses</i> , 2014, 82, 795.	1.5	7
251	Obstructive Sleep Apnea and Environmental Contributors for Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1055-1056.	4.4	4
252	A proposed role of human defensins in <i>Helicobacter pylori</i> -related neurodegenerative disorders. <i>Medical Hypotheses</i> , 2014, 82, 368-373.	1.5	36

#	ARTICLE	IF	CITATIONS
253	Additional data on Helicobacter pylori and hepatitis C virus infections and lymphoma association. European Journal of Internal Medicine, 2014, 25, e7-e8.	2.2	2
254	Bone and Fat Interplay in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, E22.	1.9	1
255	Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study. Open Cardiovascular Medicine Journal, 2014, 8, 55-60.	0.3	18
256	infection and liver cirrhosis: possible association with hepatic encephalopathy and/or post-hepatic encephalopathy cognitive impairment in patients with portal hypertension. Annals of Gastroenterology, 2014, 27, 285.	0.6	4
257	Patients with established gastro-esophageal reflux disease might benefit from eradication. Annals of Gastroenterology, 2014, 27, 352-356.	0.6	5
258	Potential Oncogenic Properties of Mobilized Stem Cells in a Subpopulation of Inflammatory Bowel Disease Patients Infected with Helicobacter pylori. Inflammatory Bowel Diseases, 2013, 19, E27-E29.	1.9	7
259	Predictors of long-term remission in patients with Graves' disease: a single center experience. Endocrine, 2013, 44, 448-453.	2.3	60
260	Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3206-3212.	3.6	46
261	Coexistence of Graves' disease, papillary thyroid carcinoma and unilateral benign struma ovarii: Case report and review of the literature. Metabolism: Clinical and Experimental, 2013, 62, 1350-1356.	3.4	20
262	Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy. Advances in Medical Sciences, 2013, 58, 38-43.	2.1	4
263	A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study. Biomarkers, 2013, 18, 607-613.	1.9	16
264	Thyrotropin receptor autoantibodies and early miscarriages in patients with Hashimoto thyroiditis: a case-control study. Gynecological Endocrinology, 2013, 29, 793-796.	1.7	2
265	Helicobacter pylori Infection and Serum Adiponectin. Helicobacter, 2013, 18, 321-322.	3.5	6
266	Is Helicobacter pylori the usual suspect behind gastroesophageal reflux disease and dacryostenosis?. Medical Hypotheses, 2013, 81, 147.	1.5	3
267	Aquaporin 4, Helicobacter pylori and potential implications for neuromyelitis optica. Journal of Neuroimmunology, 2013, 263, 162-163.	2.3	7
268	Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2013, 62, 121-126.	3.4	130
269	Irisin: A renaissance in metabolism?. Metabolism: Clinical and Experimental, 2013, 62, 1037-1044.	3.4	113
270	Leptin at the Intersection of Neuroendocrinology and Metabolism: Current Evidence and Therapeutic Perspectives. Cell Metabolism, 2013, 18, 29-42.	16.2	178

#	ARTICLE	IF	CITATIONS
271	Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. <i>Clinical Endocrinology</i> , 2013, 79, 499-503.	2.4	52
272	<i>Helicobacter pylori</i> Infection and Insulin Resistance. <i>Helicobacter</i> , 2013, 18, 165-166.	3.5	12
273	Serum vaspin levels in women with and without gestational diabetes mellitus during pregnancy and postpartum. <i>Cytokine</i> , 2013, 61, 127-132.	3.2	20
274	Leptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals. <i>Endocrine Reviews</i> , 2013, 34, 377-412.	20.1	212
275	Relationship between <i>Helicobacter pylori</i> infection and autoimmune disorders. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, e73-4.	2.3	3
276	Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms. <i>Obesity Reviews</i> , 2013, 14, 1006-1022.	6.5	61
277	Impact of <i>Helicobacter pylori</i> Infection on Colon Oncogenesis. <i>American Journal of Gastroenterology</i> , 2013, 108, 625-626.	0.4	11
278	<i>Helicobacter pylori</i> induced cognitive dysfunction might be associated with falls and fractures in cirrhosis. <i>Hepatology</i> , 2013, 57, 1284-1284.	7.3	9
279	Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease. <i>Hormones</i> , 2013, 12, 405-416.	1.9	49
280	Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. <i>Annals of Hepatology</i> , 2013, 12, 749-757.	1.5	29
281	Comment on: Jeon et al. <i>Helicobacter pylori</i> Infection Is Associated With an Increased Rate of Diabetes. <i>Diabetes Care</i> 2012;35:520-525. <i>Diabetes Care</i> , 2012, 35, e53-e53.	8.6	1
282	Re: <i>Helicobacter Pylori</i> Infection and Colorectal Cancer Risk: Evidence From a Large Population-Based Case-Control Study in Germany. <i>American Journal of Epidemiology</i> , 2012, 176, 566-567.	3.4	25
283	Is Serum IL-17A a Useful Systemic Biomarker in Patients With Langerhans Cell Histiocytosis?. <i>Molecular Therapy</i> , 2012, 20, 6-7.	8.2	11
284	Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell Histiocytosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E618-E621.	3.6	10
285	Editorial [Hot Topic Adiponectin in Health and Disease: Current Evidence and Therapeutic Perspectives (Guest Editor: Stergios A. Polyzos)]. <i>Current Medicinal Chemistry</i> , 2012, 19, 5425-5426.	2.4	3
286	The Emerging Role of Endocrine Disruptors in Pathogenesis of Insulin Resistance: A Concept Implicating Nonalcoholic Fatty Liver Disease. <i>Current Molecular Medicine</i> , 2012, 12, 68-82.	1.3	85
287	Histological Presence of <i>Helicobacter pylori</i> ; Bacteria in the Trabeculum and Iris of Patients with Primary Open-Angle Glaucoma. <i>Ophthalmic Research</i> , 2012, 47, 150-156.	1.9	44
288	Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 272-284.	2.2	124

#	ARTICLE	IF	CITATIONS
289	<i>Helicobacter pylori</i> 's potential association with epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2012, 21, 151.	2.0	2
290	<i>Helicobacter pylori</i> may play a role in both obstructive sleep apnea and metabolic syndrome. <i>Sleep Medicine</i> , 2012, 13, 212-213.	1.6	11
291	A potential impact of chronic <i>Helicobacter pylori</i> infection on Alzheimer's disease pathobiology and course. <i>Neurobiology of Aging</i> , 2012, 33, e3-e4.	3.1	83
292	<i>Helicobacter pylori</i> Infection Might Contribute to Esophageal Adenocarcinoma Progress in Subpopulations With Gastroesophageal Reflux Disease and Barrett's Esophagus. <i>Helicobacter</i> , 2012, 17, 402-403.	3.5	19
293	Hpn protein as a mediator between <i>Helicobacter pylori</i> infection and Alzheimer's disease in sub-populations worldwide. <i>Medical Hypotheses</i> , 2012, 78, 349-350.	1.5	4
294	Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. <i>Bone</i> , 2012, 50, 1130-1134.	2.9	30
295	The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass. <i>Clinical Endocrinology</i> , 2012, 77, 816-822.	2.4	6
296	Serum vitamin B12 and folate levels in patients with non-alcoholic fatty liver disease. <i>International Journal of Food Sciences and Nutrition</i> , 2012, 63, 659-666.	2.8	27
297	Glaucoma and <i>Helicobacter pylori</i> : Eyes "wide open". <i>Digestive and Liver Disease</i> , 2012, 44, 962-963.	0.9	6
298	Potential implications of <i>Helicobacter pylori</i> -related neutrophil-activating protein. <i>World Journal of Gastroenterology</i> , 2012, 18, 489.	3.3	14
299	Acute transient thyroid swelling following needle biopsy: An update. <i>Hormones</i> , 2012, 11, 147-150.	1.9	14
300	Papillary thyroid microcarcinoma presenting as lymph node metastasis "a diagnostic challenge: case report and systematic review of literature. <i>Hormones</i> , 2012, 11, 419-427.	1.9	7
301	Further data on the association between <i>Helicobacter pylori</i> infection and primary open-angle glaucoma. <i>Clinical Ophthalmology</i> , 2012, 6, 243.	1.8	4
302	Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 295.	2.0	69
303	Trying to treat diabetes in Greek crisis. <i>International Journal of Clinical Practice</i> , 2012, 66, 515-515.	1.7	3
304	Long-term effects of thyroid fine-needle biopsy on the thyroid-related biochemical parameters. <i>International Journal of Clinical Practice</i> , 2012, 66, 602-609.	1.7	2
305	Sulfated oxysterols as candidates for the treatment of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 755-758.	3.4	4
306	<i>Helicobacter pylori</i> infection and Parkinson's disease: apoptosis as an underlying common contributor. <i>European Journal of Neurology</i> , 2012, 19, e56.	3.3	32

#	ARTICLE	IF	CITATIONS
307	Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide. <i>Osteoporosis International</i> , 2012, 23, 1171-1176.	3.1	111
308	A rebuttal to the potential anti-tumour benefit of <i>Helicobacter pylori</i> -induced neutrophil-activating protein. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 445-446.	4.2	1
309	Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. <i>Pituitary</i> , 2012, 15, 25-29.	2.9	47
310	Ki-67 and Bax expression in esophageal mucosa might have implications in ablative therapies for Barrett's esophagus, dysplasia, and adenocarcinoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 283-284.	2.4	1
311	<i>Helicobacter pylori</i> infection and colorectal carcinoma: pathologic aspects. <i>Journal of Gastrointestinal Oncology</i> , 2012, 3, 377-9.	1.4	23
312	Visual Vignette. <i>Endocrine Practice</i> , 2012, 18, 108.	2.1	0
313	Serum homocysteine levels in patients with nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2012, 11, 68-76.	1.5	20
314	Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid. <i>Endokrynologia Polska</i> , 2012, 63, 312-5.	1.0	0
315	<i>Helicobacter pylori</i> Might Contribute to Persistent Cognitive Impairment After Resolution of Overt Hepatic Encephalopathy. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 624.	4.4	12
316	<i>Helicobacter pylori</i> infection may trigger Guillain-Barré syndrome, Fisher syndrome and Bickerstaff brainstem encephalitis. <i>Journal of the Neurological Sciences</i> , 2011, 305, 167-168.	0.6	12
317	<i>Helicobacter pylori</i> Infection as a Risk Factor for Both Primary Open-Angle Glaucoma and Pseudoexfoliative Glaucoma in Thessaloniki Eye Study. <i>American Journal of Ophthalmology</i> , 2011, 152, 1079-1080.	3.3	7
318	<i>Helicobacter pylori</i> may play an important role in both axonal type Guillain-Barré syndrome and acute inflammatory demyelinating polyradiculoneuropathy. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 520.	1.4	8
319	Neuroprotection in glaucoma: Is there a future role of <i>Helicobacter pylori</i> eradication?. <i>Experimental Eye Research</i> , 2011, 92, 436-438.	2.6	17
320	<i>Helicobacter pylori</i> infection and the risk for cardiovascular disease. <i>European Journal of Internal Medicine</i> , 2011, 22, e146-e147.	2.2	17
321	<i>Helicobacter pylori</i> might be a potential therapeutic target in epilepsy. <i>Medical Hypotheses</i> , 2011, 76, 763.	1.5	7
322	Modern industrialisation may increase primary open-angle glaucoma prevalence through easier transmission of <i>Helicobacter pylori</i> infection. <i>Medical Hypotheses</i> , 2011, 76, 766-767.	1.5	3
323	Denosumab and bisphosphonates: Rivals or potential "copartners"? A "hybrid" molecule hypothesis. <i>Medical Hypotheses</i> , 2011, 77, 109-111.	1.5	4
324	Upper Gastrointestinal Carcinogenesis: <i>H. pylori</i> and Stem Cell Cross-Talk. <i>Journal of Surgical Research</i> , 2011, 166, 255-264.	1.6	31

#	ARTICLE	IF	CITATIONS
325	Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. <i>Hormones</i> , 2011, 10, 174-195.	1.9	23
326	The Potential Adverse Role of Leptin Resistance in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 50-54.	2.2	69
327	<i>Helicobacter pylori</i> may be involved in stroke pathophysiology by altering tumor necrosis factor- $\alpha$ and matrix metalloproteinases. <i>European Journal of Neurology</i> , 2011, 18, e76-e76.	3.3	1
328	Multiple sclerosis and seizures: possible role of <i>Helicobacter pylori</i> . <i>European Journal of Neurology</i> , 2011, 18, e116-e116.	3.3	9
329	Pituitary incidentalomas: a single-centre experience. <i>International Journal of Clinical Practice</i> , 2011, 65, 172-177.	1.7	32
330	Adiponectin in non-alcoholic fatty liver disease treatment: therapeutic perspectives and unresolved dilemmas. <i>International Journal of Clinical Practice</i> , 2011, 65, 373-374.	1.7	12
331	Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. <i>International Journal of Clinical Practice</i> , 2011, 65, 679-683.	1.7	37
332	Acromegaly: presentation, morbidity and treatment outcomes at a single centre. <i>International Journal of Clinical Practice</i> , 2011, 65, 896-902.	1.7	35
333	Irritable bowel syndrome associated with mitral valve prolapse and autonomic and haemostatic abnormalities in children, adolescents and adults with migraine. <i>Acta Neurologica Scandinavica</i> , 2011, 123, 366-367.	2.1	2
334	Spironolactone Revisited. <i>Journal of Clinical Hypertension</i> , 2011, 13, 783-784.	2.0	0
335	Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 313-326.	3.4	272
336	Impact of <i>Helicobacter pylori</i> on chronic hepatitis C-related cognitive dysfunction. <i>Journal of Neuroimmunology</i> , 2011, 233, 254-256.	2.3	10
337	<i>Helicobacter pylori</i> may be a common denominator associated with systemic and multiple sclerosis. <i>Joint Bone Spine</i> , 2011, 78, 222-223.	1.6	13
338	The Association Between <i>Helicobacter pylori</i> Infection and Insulin Resistance: A Systematic Review. <i>Helicobacter</i> , 2011, 16, 79-88.	3.5	175
339	Association between <i>Helicobacter pylori</i> infection and Alzheimer's disease in Japan. <i>Journal of Neurology</i> , 2011, 258, 2086-2086.	3.6	11
340	Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone. <i>Clinical Rheumatology</i> , 2011, 30, 149-150.	2.2	1
341	Association between <i>Helicobacter pylori</i> infection and fibromyalgia syndrome. <i>Clinical Rheumatology</i> , 2011, 30, 301-302.	2.2	1
342	Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone. <i>Osteoporosis International</i> , 2011, 22, 363-367.	3.1	17

#	ARTICLE	IF	CITATIONS
343	No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase Response. <i>Calcified Tissue International</i> , 2011, 88, 402-408.	3.1	18
344	Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases. <i>Current Molecular Medicine</i> , 2011, 11, 696-707.	1.3	45
345	Paget's Disease of Bone and Calcium Homeostasis: Focus on Bisphosphonate Treatment. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2011, 119, 519-524.	1.2	15
346	Role of wntless tail signaling pathway in osteoporosis. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2011, 18, 383-388.	2.3	18
347	Multiple Sclerosis, Idiopathic Dilated Cardiomyopathy, and Insulin-dependent Diabetes Mellitus. <i>Neurologist</i> , 2011, 17, 172-175.	0.7	5
348	<i>Helicobacter pylori</i> and insulin resistance association: Not just a myth, not yet a fact. <i>Saudi Journal of Gastroenterology</i> , 2011, 17, 425.	1.1	4
349	Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011, 12, 498-503.	1.7	44
350	The potentially dual-faceted nature of fetuin-A in <i>Helicobacter pylori</i> infection and insulin resistance. <i>Clinics</i> , 2011, 66, 911-912.	1.5	7
351	Coincidental thyroid papillary microcarcinoma in a patient treated for a toxic adenoma of the thyroid. <i>Archives of Iranian Medicine</i> , 2011, 14, 149-51.	0.6	3
352	The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. <i>Clinical Endocrinology</i> , 2010, 72, 752-757.	2.4	52
353	Nonlinear Distribution of Adiponectin in Patients With Nonalcoholic Fatty Liver Disease Limits Its Use in Linear Regression Analysis. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 229-230.	2.2	19
354	A Systematic Review of Cases Reporting Needle Tract Seeding Following Thyroid Fine Needle Biopsy. <i>World Journal of Surgery</i> , 2010, 34, 844-851.	1.6	46
355	Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 108-110.	2.7	4
356	Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 314-319.	2.7	8
357	Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 706-712.	2.7	26
358	The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 365-383.	4.4	220
359	Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2010, 54, 578-582.	1.3	4
360	Five-year Survival After <i>Helicobacter pylori</i> Eradication in Alzheimer Disease Patients. <i>Cognitive and Behavioral Neurology</i> , 2010, 23, 199-204.	0.9	94

#	ARTICLE	IF	CITATIONS
361	Familial prevalence of autoimmune disorders in multiple sclerosis in Northern Greece. Multiple Sclerosis Journal, 2010, 16, 1091-1101.	3.0	29
362	Infectious thyroiditis as a complication of fine-needle biopsy: a systematic review. Expert Review of Endocrinology and Metabolism, 2010, 5, 673-679.	2.4	3
363	Dual-Energy X-Ray Absorptiometry and Quantitative Ultrasound in Patients With Paget's Disease of Bone Before and After Treatment With Zoledronic Acid: Association With Serum Bone Markers and Dickkopf-1. Journal of Clinical Densitometry, 2010, 13, 190-196.	1.2	3
364	Helicobacter pylori with or without its neutrophil-activating protein may be the common denominator associated with multiple sclerosis and neuromyelitis optica. Multiple Sclerosis Journal, 2010, 16, 376-377.	3.0	17
365	Adipocytokines in insulin resistance and non-alcoholic fatty liver disease: The two sides of the same coin. Medical Hypotheses, 2010, 74, 1089-1090.	1.5	19
366	Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis. Hepatology Research, 2010, 40, 446-447.	3.4	15
367	Alterations in Serum Thyroid-Related Constituents After Thyroid Fine-Needle Biopsy: A Systematic Review. Thyroid, 2010, 20, 265-271.	4.5	21
368	Systematic review of cases reporting blood extravasation-related complications after thyroid fine-needle biopsy. Journal of Otolaryngology - Head and Neck Surgery, 2010, 39, 532-41.	1.9	11
369	Helicobacter pylori: an intruder involved in conspiring glaucomatous neuropathy. British Journal of Ophthalmology, 2009, 93, 1413-1415.	3.9	40
370	Effect of Strontium Ranelate on Lumbar Spine Bone Mineral Density in Women with Established Osteoporosis Previously Treated with Teriparatide. Hormone and Metabolic Research, 2009, 41, 559-562.	1.5	10
371	The Use of Demographic, Ultrasonographic and Scintigraphic Data in the Diagnostic Approach of Thyroid Nodules. Experimental and Clinical Endocrinology and Diabetes, 2009, 117, 159-164.	1.2	17
372	Nonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines. Current Molecular Medicine, 2009, 9, 299-314.	1.3	270
373	The Effect of Zoledronic Acid on Serum Dickkopf-1, Osteoprotegerin, and RANKL in Patients with Paget's Disease of Bone. Hormone and Metabolic Research, 2009, 41, 846-850.	1.5	24
374	Increased Cerebrospinal Fluid Helicobacter Pylori Antibody in Alzheimer's Disease. International Journal of Neuroscience, 2009, 119, 765-777.	1.6	96
375	A concept of Helicobacter pylori and stress-secreted mast cells' potential involvement in brain metastases. Journal of Neuroimmunology, 2009, 209, 121-122.	2.3	18
376	Histological alterations following thyroid fine needle biopsy: A systematic review. Diagnostic Cytopathology, 2009, 37, 455-465.	1.0	28
377	Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. Supportive Care in Cancer, 2009, 17, 1329-1330.	2.2	13
378	Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. Journal of Neurology, 2009, 256, 758-767.	3.6	150

#	ARTICLE	IF	CITATIONS
379	Clinical complications following thyroid fine-needle biopsy: a systematic review. <i>Clinical Endocrinology</i> , 2009, 71, 157-165.	2.4	149
380	No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial. <i>Clinical Endocrinology</i> , 2009, 70, 522-526.	2.4	8
381	The effect of zoledronic acid on serum Dickkopf-1, osteoprotegerin and rankl in patients with paget's disease of bone. <i>Bone</i> , 2009, 44, S289.	2.9	1
382	Insulin resistance and therapy: Cross-talk between phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways. <i>Medical Hypotheses</i> , 2009, 72, 610.	1.5	1
383	From the "little brain" gastrointestinal infection to the "big brain" neuroinflammation: A proposed fast axonal transport pathway involved in multiple sclerosis. <i>Medical Hypotheses</i> , 2009, 73, 781-787.	1.5	31
384	Paget's disease of bone: emphasis on treatment with zoledronic acid. <i>Expert Review of Endocrinology and Metabolism</i> , 2009, 4, 423-434.	2.4	10
385	RANKL inhibition for the management of patients with benign metabolic bone disorders. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1085-1102.	4.1	30
386	Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 183-189.	1.6	28
387	Effects of mastic gum <i>Pistacia lentiscus</i> var. <i>Chia</i> on innate cellular immune effectors. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 143-149.	1.6	30
388	Primary open-angle glaucoma. <i>New England Journal of Medicine</i> , 2009, 360, 2679; author reply 2679-80.	27.0	2
389	Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone. <i>Journal of Bone and Mineral Metabolism</i> , 2008, 26, 635-641.	2.7	30
390	Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 953-960.	2.5	90
391	Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. <i>International Journal of Clinical Practice</i> , 2008, 62, 919-924.	1.7	23
392	<i>Helicobacter pylori</i> infection as a risk factor for primary open-angle glaucoma. <i>Clinical and Experimental Ophthalmology</i> , 2008, 36, 196-196.	2.6	12
393	Guillain-Barré syndrome. <i>Lancet Neurology</i> , The, 2008, 7, 1080-1081.	10.2	30
394	New Aspects of <i>Helicobacter pylori</i> Infection Involvement in Gastric Oncogenesis. <i>Journal of Surgical Research</i> , 2008, 146, 149-158.	1.6	62
395	<i>Helicobacter pylori</i> may hold a variable role in multiple sclerosis based on ethnicity. <i>Medical Hypotheses</i> , 2008, 71, 614-615.	1.5	14
396	Acute changes in serum osteoprotegerin and receptor activator for nuclear factor- $\kappa$ B ligand levels in women with established osteoporosis treated with teriparatide. <i>European Journal of Endocrinology</i> , 2008, 158, 411-415.	3.7	29

#	ARTICLE	IF	CITATIONS
397	New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer. <i>Current Molecular Medicine</i> , 2008, 8, 12-37.	1.3	24
398	Epidemiologic Analysis of Thyroid Fine Needle Aspiration Biopsies over a Period of 18 Years (1987-2004). <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2008, 116, 496-500.	1.2	8
399	Sustained Clinical Inactivity and Stabilization of GH/IGF-1 Levels in an Acromegalic Patient after Discontinuation of Somatostatin Analogue Treatment. <i>Endocrine Journal</i> , 2008, 55, 351-357.	1.6	4
400	Endogenous Intact PTH is Suppressed during Teriparatide (rhPTH 1-34) Administration in Postmenopausal Women with Established Osteoporosis. <i>Endocrine Journal</i> , 2008, 55, 613-616.	1.6	15
401	Subendothelial Carotid Hematoma After Fine-Needle Aspiration Biopsy of a Solitary Thyroid Nodule. <i>Journal of Ultrasound in Medicine</i> , 2008, 27, 1517-1520.	1.7	16
402	Greek and Israeli Patterns of <i>Helicobacter pylori</i> Infection and Their Association With Glaucoma: Similarities or Diversities?. <i>Journal of Glaucoma</i> , 2008, 17, 503-504.	1.6	8
403	<i>Helicobacter pylori</i> may be involved in cognitive impairment and dementia development through induction of atrophic gastritis, vitamin B-12-folate deficiency, and hyperhomocysteinemia sequence. <i>American Journal of Clinical Nutrition</i> , 2007, 86, 805-806.	4.7	27
404	Alzheimer's disease and <i>Helicobacter pylori</i> infection: Defective immune regulation and apoptosis as proposed common links. <i>Medical Hypotheses</i> , 2007, 68, 378-388.	1.5	71
405	Normal-tension glaucoma and Alzheimer's disease: <i>Helicobacter pylori</i> as a possible common underlying risk factor. <i>Medical Hypotheses</i> , 2007, 68, 228-229.	1.5	32
406	Eradication of <i>Helicobacter pylori</i> might halt the progress to oesophageal adenocarcinoma in patients with gastro-oesophageal reflux disease and Barrett's oesophagus. <i>Medical Hypotheses</i> , 2007, 68, 1174-1175.	1.5	14
407	Challenge in the Pathogenesis of Autoimmune Pancreatitis: Potential Role of <i>Helicobacter pylori</i> Infection via Molecular Mimicry. <i>Gastroenterology</i> , 2007, 133, 368-369.	1.3	54
408	<i>Helicobacter pylori</i> and multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2007, 188, 187-189.	2.3	50
409	Thyroid nodules - Stepwise diagnosis and management. <i>Hormones</i> , 2007, 6, 101-119.	1.9	74
410	<i>Helicobacter pylori</i> and gastro-oesophageal reflux disease. <i>Lancet, The</i> , 2006, 368, 986.	13.7	25
411	Pathogenetic links between colorectal neoplasia and Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2006, 64, 298.	1.0	10
412	Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. <i>Journal of Surgical Oncology</i> , 2005, 90, 249-259.	1.7	23
413	New Molecular Concepts of Barrett's Esophagus: Clinical Implications and Biomarkers. <i>Journal of Surgical Research</i> , 2005, 125, 189-212.	1.6	44
414	Induction of Interleukin-8 Expression by <i>Helicobacter Pylori</i> Infection in Patients with Endoscopy-Negative Gastroesophageal Reflux Disease. <i>American Journal of Gastroenterology</i> , 2004, 99, 2500-2501.	0.4	9

#	ARTICLE	IF	CITATIONS
415	Induction of apoptosis as a proposed pathophysiological link between glaucoma and Helicobacter pylori infection. <i>Medical Hypotheses</i> , 2004, 62, 378-381.	1.5	51
416	Primary open-angle glaucoma: pathophysiology and treatment. <i>Lancet, The</i> , 2004, 364, 1311-1312.	13.7	50
417	Increased levels of Helicobacter pylori IgG antibodies in aqueous humor of patients with primary open-angle and exfoliation glaucoma. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2003, 241, 884-890.	1.9	77
418	Helicobacter pylori and glaucoma. <i>Ophthalmology</i> , 2003, 110, 2433-2434.	5.2	13
419	Eradication of Helicobacter pylori May Be Beneficial in the Management of Chronic Open-Angle Glaucoma. <i>Archives of Internal Medicine</i> , 2002, 162, 1237.	3.8	103
420	Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis. <i>Hormones</i> , 2002, 13, 519-31.	1.9	21
421	Relationship between Helicobacter pylori infection and glaucoma <sup>11</sup> The authors have no commercial interests in the products or devices mention herein.. <i>Ophthalmology</i> , 2001, 108, 599-604.	5.2	130
422	Potential Impact of Active H. pylori Infection-Related Metabolic Syndrome on Preeclampsia Among Pregnant Women [Letter]. <i>International Journal of Women's Health</i> , 0, Volume 14, 845-846.	2.6	0